Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Henry Luu

Addiction Medicine West Chester, PA Doctor of Osteopathy

NPI 1306864947 CMS profile 285747

1450 E Boot Rd Ste 200C, West Chester, PA 19380

Open in the dashboard

General payments

$4,666

143 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Henry Luu of West Chester, PA is reported in the CMS Open Payments database as having received $4,666 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,017 27
2024 General $784 33
2023 General $1,090 27
2022 General $800 28
2021 General $671 14
2020 General $81 4
2019 General $223 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Henry Luu
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Henry Luu were reported at $1,017. Among 306 Addiction Medicine profiles paid that year, the median was $147 and the middle half received between $46 and $381.

Show as a table
Year Henry Luu Addiction Medicine median Middle half National median
2019 $223 $96 $32–$265 $163
2020 $81 $53 $20–$176 $114
2021 $671 $86 $24–$265 $132
2022 $800 $89 $27–$330 $149
2023 $1,090 $102 $39–$363 $160
2024 $784 $110 $38–$311 $164
2025 $1,017 $147 $46–$381 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Braeburn Inc. $829 26 payments
  2. Novo Nordisk Inc $807 12 payments
  3. Indivior Inc. $639 33 payments
  4. AbbVie, Inc. $636 11 payments
  5. Corium, Inc. $588 25 payments
  6. AstraZeneca Pharmaceuticals LP $361 4 payments
  7. Gilead Sciences, Inc. $177 5 payments
  8. Lilly USA, LLC $115 1 payment
  9. Adlon Therapeutics L.P. $98 5 payments
  10. Orexo US, Inc. $94 6 payments
  11. Other $321 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,653 142 payments
  2. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. BRIXADI $829 26 payments
  2. MAVYRET $620 10 payments
  3. SUBLOCADE $614 31 payments
  4. Azstarys $588 25 payments
  5. RYBELSUS $558 10 payments
  6. Ozempic $350 8 payments
  7. FARXIGA $248 3 payments
  8. MOUNJARO $115 1 payment
  9. BREZTRI $113 1 payment
  10. Epclusa $107 1 payment
  11. Other $554 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

518

Median for Family Practice: 1,826

Drug cost

$149,470

Median for Family Practice: $120,094

Branded share of claims

95%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 150 $45,707
Sublocade Buprenorphine Brand 16 $31,866
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 135 $28,680
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 49 $14,555
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 99 $11,780
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 15 $11,183
Vyvanse Lisdexamfetamine Dimesylate Brand 13 $4,957
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 15 $367
Sertraline Hcl Generic 13 $353
Clonidine Hcl Generic 13 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIXADI
  • Braeburn Inc. $390
$390 — —
SUBLOCADE
  • Indivior Inc. $156
$156 16 —
Azstarys
  • Corium, Inc. $149
$149 — —
VIVITROL
  • Alkermes, Inc. $28
$28 — —
Relexxii
  • Vertical Pharmaceuticals, LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record